A fortnightly dosing safety study AVA6000

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Dec 2023 According to an Avacta media release, this study is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.
03 Oct 2023 New trial record
28 Sep 2023 According to an Avacta media release, the company plans to initiate a fortnightly dosing safety study in order to determine the dosing regimen for a Phase 2 registrational study in soft tissue sarcoma. This is short study in place of the much longer multi-arm Phase 1b efficacy study previously envisaged, anticipated to be completed by the middle of 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com